title: CacyBP/SIP inhibits Doxourbicin-induced apoptosis of glioma cells due to activation of ERK1/2.
abstract: Calcyclin-binding protein or Siah-1-interacting protein (CacyBP/SIP) was previously reported to promote the proliferation of glioma cells. However, the effect of CacyBP/SIP on apoptosis of glioma is poorly understood. Here, our study shows that CacyBP/SIP plays a role in inhibiting doxorubicin (DOX) induced apoptosis of glioma cells U251 and U87. Overexpression of CacyBP/SIP obviously suppressed the DOX-induced cell apoptosis. On the contrary, silencing of CacyBP/SIP significantly promoted it. Further investigation indicated that inhibition of apoptosis by CacyBP/SIP was relevant to its nuclear translocation in response to the DOX treatment. Importantly, we found that the level of p-ERK1/2 in nuclei was related to the nuclear accumulation of CacyBP/SIP. Finally, the role of CacyBP/SIP was confirmed in vivo in a mouse model with the cell line stably silencing CacyBP/SIP. Taken together, our results suggest that CacyBP/SIP plays an important role in inhibiting apoptosis of glioma cells which might be mediated by ERK1/2 signaling pathway, which will provide some guidance for the treatment of glioma.
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Brain Hospital, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Wenjian
authors.initials: W
authors.lastname: Zhan
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Tong
authors.initials: T
authors.lastname: Cao
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Tianjin
authors.initials: T
authors.lastname: Tang
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Qiu
authors.affiliation: Institute of Blood Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Chunling
authors.initials: C
authors.lastname: Fu
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Department of clinical medicine, The Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Fengyuan
authors.initials: F
authors.lastname: Qian
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Brain Hospital, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Rutong
authors.initials: R
authors.lastname: Yu
authors.affiliation: Insititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, China.|Brain Hospital, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors.forename: Hengliang
authors.initials: H
authors.lastname: Shi
mesh_terms: D021581:Active Transport, Cell Nucleus; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002135:Calcium-Binding Proteins / Q000502:physiology*; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000201:enzymology; D018450:Disease Progression; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D020935:MAP Kinase Signaling System; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D047368:Tumor Burden; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000903:Antibiotics, Antineoplastic; C491778:CACYBP protein, human; D002135:Calcium-Binding Proteins; D004317:Doxorubicin
keywords: CacyBP/SIP; ERK1/2; apoptosis; chemotherapy; glioma